The ability of a substance to provoke an immune response. Some peptides can trigger anti-drug antibody formation over time, potentially reducing efficacy or causing allergic reactions.
"Immunogenicity" is filed under Clinical & Safety in the PeptideAtlas glossary, alongside 15 other terms in that group.
The term applies directly to 2 compound profiles here: Dulaglutide (evidence A), P21 (evidence D). Each profile states the strength of the human evidence rather than only what the compound is claimed to do.
A condition or factor that makes a particular treatment or procedure inadvisable. Absolute contraindications mean the treatment should never be used; relative contraindications mean the benefits may outweigh risks in some cases.
Any undesirable experience associated with the use of a medical product, whether or not considered related to the product. Serious adverse events include hospitalization, disability, or life-threatening outcomes.
The FDA's most serious warning placed on a drug's prescribing information, indicating significant risks of serious or life-threatening adverse effects. GLP-1 agonists carry a black box warning for thyroid C-cell tumors based on rodent studies.
Compounds where this applies: Dulaglutide, P21.
More Clinical & Safety terms: Contraindication, Adverse Event, Black Box Warning, Therapeutic Window, Drug Interaction, Washout Period, Anaphylaxis, Anti-Drug Antibodies (ADA), MedWatch, REMS (Risk Evaluation and Mitigation Strategy), Gastroparesis, Pancreatitis, Gallbladder Disease, Injection Site Reaction, Sterile Abscess.